Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time

María Mora González López Ledesma, Lautaro Sánchez, Diego Ojeda, Santiago Oviedo Rouco, Andrés H. Rossi, Augusto Varese, Ignacio Mazzitelli, Carla A. Pascuale, Esteban Miglietta, Pamela Elizabeth Rodríguez, Horacio M. Pallarés, Guadalupe S. Costa Navarro, Julio J. Caramelo, Paul W. Rothlauf, Zhuoming Liu, Louis-Marie Bloyet, Marjorie Cornejo Pontelli, Natalí B. Rasetto, Shirley D. Wenker, Lila Y. Ramis, Magalí G. Bialer, María José de Leone, Carlos Esteban Hernando, Luciana Bianchimano, Antonella S. Ríos, María Soledad Treffinger Cienfuegos, Diana Rosa Rodríguez Garcia, Yésica Longueira, Natalia Laufer, Diego E. Álvarez, Ana Ceballos, Valeria Ochoa, Cecilia Monzani, Gariela Turk, Melina Salvatori, Jorge Carradori, Katherine Prost, Alejandra Rima, Claudia Varela, Regina Ercole, Rosana Toro, Sebastián Gutiérrez, Martín Zubieta, Dolores Acuña, Mercedes Soledad Nabaes Jodar, Carolina Torres, Laura Mojsiejczuk, Mariana Viegas, Pilar Velazquez, Clarisa Testa, Nicolás Kreplak, Marcelo J. Yanovsky, Sean P. J. Whelan, Jorge Geffner, Marina Pífano, Andrea V. GamarnikmBio 2022 · DOI

TL;DR

This study tracked antibody responses in individuals vaccinated with Sputnik V in Argentina over six months. While overall antibody levels decreased, the ability of these antibodies to neutralize SARS-CoV-2, including concerning variants like Beta and Gamma, remained strong and even improved over time, suggesting a robust and adaptable immune memory.

What Problem Does This Paper Address?

The rapid development and deployment of COVID-19 vaccines have been crucial in combating the pandemic. However, understanding the long-term durability and breadth of the immune response elicited by different vaccine platforms, especially against emerging viral variants, is critical for assessing vaccine effectiveness and informing public health strategies. Sputnik V, a widely used adenovirus-based vaccine, particularly in regions with limited access to other vaccines, lacked comprehensive longitudinal data on its antibody response against various SARS-CoV-2 strains. This paper addresses this gap by investigating how antibody levels and neutralizing capacity against the original virus and key variants change over time after Sputnik V vaccination.

Methods

The researchers conducted a longitudinal study, collecting serum samples from 118 volunteers who received the Sputnik V vaccine in Argentina. Samples were collected at five time points: before vaccination (baseline) and at 21, 42, 120, and 180 days after the initial vaccination.

Key techniques employed include:

  • Anti-spike IgG antibody quantification: Measured using a standardized ELISA kit and the WHO International Antibody Standard to quantify the overall antibody response.
  • Viral neutralization assays: This was performed using two main systems:
  • Pseudotyped virus system: Vesicular stomatitis virus (VSV) engineered to express the SARS-CoV-2 spike protein from the Wuhan strain and several variants of concern (Alpha, Beta, Gamma, Delta). This system allowed for the assessment of neutralizing capacity against specific variants.
  • Replicating virus system: Used local isolates of SARS-CoV-2, including the B.1 lineage (Wuhan-related) and regional variants (Alpha, Gamma, Lambda), to assess neutralization against viruses circulating in Argentina.
  • Neutralization Index Calculation: This was used to assess the relationship between antibody levels and neutralizing potency, indicating potential antibody maturation.
  • Statistical Analysis: Standard statistical tests (Wilcoxon matched-pair test, Mann-Whitney U test) were used to analyze the data and determine significance.

Datasets

The study utilized longitudinal serum samples collected from 118 volunteers in Argentina between January and October 2021. A total of 536 serum samples were analyzed. The study also referenced publicly available data for SARS-CoV-2 variants (e.g., GISAID accession numbers). No new benchmarks were introduced; rather, existing methods for antibody quantification and neutralization assays were applied.

Key Insights and Ideas

  • Antibody Waning vs. Neutralization Stability: A key finding is the divergence between overall anti-spike IgG levels and neutralizing capacity. While IgG levels decline significantly over six months, the ability to neutralize the virus remains robust. This suggests that the quality of the antibody response, rather than just the quantity, is crucial for protection.
  • Maturing Immune Response: The study observed an increase in cross-neutralizing ability against certain variants (Beta and Gamma) over time. This phenomenon, also seen in convalescent individuals, points towards antibody affinity maturation, where antibodies become more effective at binding and neutralizing diverse viral strains.
  • Reduced Variant Escape: The variants that initially showed higher "escape" from neutralization (Beta and Gamma) were precisely those where the neutralizing susceptibility increased over time post-vaccination. This is a significant finding, indicating that the immune system adapts to better combat these more challenging variants.
  • Sputnik V's Broad Efficacy: The results demonstrate that Sputnik V elicits a durable neutralizing response not only against the original SARS-CoV-2 strain but also against key variants of concern, highlighting its potential for broad protection.

Key Results

  • Anti-spike IgG levels: For individuals who were seronegative at baseline, IgG levels declined from a geometric mean of 732 IU/mL at 42 days post-vaccination to 64 IU/mL at 180 days. Similar declines were observed in previously infected individuals.
  • Neutralizing capacity: Despite the IgG decline, the geometric mean half-maximal neutralizing titer (GMT IC50) in naive individuals showed only a ~2-fold reduction over six months, decreasing from 112 to 44.
  • Variant Neutralization (42 days post-vaccination): Neutralizing activity against Alpha and Delta variants showed a 2.5- and 5.1-fold decrease, respectively, compared to the Wuhan strain. Beta and Gamma variants showed a more significant reduction (19.2-fold and 13.8-fold, respectively).
  • Variant Neutralization (120 days post-vaccination): Neutralizing activity against Alpha, Beta, Gamma, and Delta variants showed 2.9-, 9.7-, 4.2-, and 3.4-fold decreases, respectively.
  • Improved Cross-Neutralization: A significant increase in relative neutralization capacity was observed over time (from 42 to 120 days) for Beta and Gamma variants compared to the Wuhan virus.
  • Lambda Variant: Neutralizing capacity against the Lambda variant showed a slight reduction (2.8- and 2.9-fold at 42 and 120 days, respectively) compared to the original B.1 virus.

Limitations and Future Work

The authors acknowledge that while antibody titers are important, they are not the sole correlate of protection. Further studies are needed to evaluate the long-term efficacy of Sputnik V vaccination against VOCs and to define precise correlates of protection based on antibody and neutralization titers. The study focused on antibody responses and did not directly assess cellular immunity. Future work could explore the cellular immune response elicited by Sputnik V and its contribution to long-term protection. Additionally, while the study included a significant number of samples, expanding the cohort size and geographical diversity could further strengthen the findings.

Summary updated

Abstract

Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOC; Alpha, Beta, Gamma, and Delta), and to a local variant of interest (VOI; Lambda) in volunteers receiving the Sputnik V vaccine in Argentina. Longitudinal serum samples (<i>N</i> = 536) collected from 118 volunteers obtained between January and October 2021 were used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing capacity for the Wuhan-related lineages of SARS-CoV-2 and VOC is maintained within 6 months of vaccination. In addition, an improved antibody cross-neutralizing ability for circulating variants of concern (Beta and Gamma) was observed over time postvaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect to the original virus (Beta and Gamma variants) were the ones showing the largest increase in susceptibility to neutralization over time after vaccination. Our observations indicate that serum neutralizing antibodies are maintained for at least 6 months and show a reduction of VOC escape to neutralizing antibodies over time after vaccination. <b>IMPORTANCE</b> Vaccines have been produced in record time for SARS-CoV-2, offering the possibility of halting the global pandemic. However, inequalities in vaccine accessibility in different regions of the world create a need to increase international cooperation. Sputnik V is a recombinant adenovirus-based vaccine that has been widely used in Argentina and other developing countries, but limited information is available about its elicited immune responses. Here, we examined longitudinal antibody levels and viral neutralizing capacity elicited by Sputnik V vaccination. Using a cohort of 118 volunteers, we found that while anti-spike antibodies wane over time, the neutralizing capacity to viral variants of concern and local variants of interest is maintained within 4 months of vaccination. In addition, we observed an increased cross-neutralization activity over time for the Beta and Gamma variants. This study provides valuable information about the immune response generated by a vaccine platform used in many parts of the world.
BibTeX
@inproceedings{ledesma2022longitudinal,
  author = {María Mora González López Ledesma and Lautaro Sánchez and Diego Ojeda and Santiago Oviedo Rouco and Andrés H. Rossi and Augusto Varese and Ignacio Mazzitelli and Carla A. Pascuale and Esteban Miglietta and Pamela Elizabeth Rodríguez and Horacio M. Pallarés and Guadalupe S. Costa Navarro and Julio J. Caramelo and Paul W. Rothlauf and Zhuoming Liu and Louis-Marie Bloyet and Marjorie Cornejo Pontelli and Natalí B. Rasetto and Shirley D. Wenker and Lila Y. Ramis and Magalí G. Bialer and María José de Leone and Carlos Esteban Hernando and Luciana Bianchimano and Antonella S. Ríos and María Soledad Treffinger Cienfuegos and Diana Rosa Rodríguez Garcia and Yésica Longueira and Natalia Laufer and Diego E. Álvarez and Ana Ceballos and Valeria Ochoa and Cecilia Monzani and Gariela Turk and Melina Salvatori and Jorge Carradori and Katherine Prost and Alejandra Rima and Claudia Varela and Regina Ercole and Rosana Toro and Sebastián Gutiérrez and Martín Zubieta and Dolores Acuña and Mercedes Soledad Nabaes Jodar and Carolina Torres and Laura Mojsiejczuk and Mariana Viegas and Pilar Velazquez and Clarisa Testa and Nicolás Kreplak and Marcelo J. Yanovsky and Sean P. J. Whelan and Jorge Geffner and Marina Pífano and Andrea V. Gamarnik},
  title = {{Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time}},
  booktitle = {mBio},
  year = {2022},
  doi = {10.1128/mbio.03442-21},
}
Figure